BRISTOL

📅 Upcoming

🕒 Recent(90d)

News

• Bristol Myers defends pipeline, reinforces later-stage BD interest
  Bristol Myers Squibb is reemphasizing its plan to stave off one of the industry’s most daunting patent cliffs. Speaking to analysts on its earnings call on Thursday, executives at the New Jersey ph…
  endpoints · 3h ago
• BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
  In addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma…
  biospace · 5h ago
• LENZ cuts 75% of staff as third quarter earnings disappoint
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 7h ago
• BMS walks away from $80M neurodegeneration bet after phase 1
  Bristol Myers Squibb has scrapped a phase 1 program it bet $80 million on just two years ago.
  fiercebiotech · 12h ago
• STAT+: Lawmaker wants government watchdog to probe TrumpRx over claims about drug savings
  A House lawmaker asked the Government Accountability Office to review whether the TrumpRx platform has saved Americans any money.
  stat · 1d ago
• STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more
  Missouri attorney general warned Eli Lilly to discontinue requiring hospitals to provide claims data to receive discounted medicines under 340B program
  stat · 1d ago
• Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
  Merck stole the show at the European Society for Medical Oncology (ESMO) annual conference, with new data on its Moderna-partnered personalized cancer vaccine leaking prior to the presentation and…
  biospace · 1d ago
• Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woes
  Astellas has struck a deal for Audax Biosciences’ IL-12 program, committing up to $285 million in upfront and option fees to secure a chance to license the preclinical immuno-oncology program.
  fiercebiotech · 1d ago
• 5 new drug launches that defied industry expectations
  A clearly superior clinical profile, reasonable pricing and easy access has helped a handful of recently approved therapies achieve impressive launches.
  biospace · 1d ago
• Big Pharma is ready to strike, with J&J most likely to buy: Leerink
  The largest pharmas have a collective $188 billion in firepower to spend on M&A transactions, with all but one signaling a desire to execute, according to a new analysis from Leerink Partners.
  biospace · 1d ago